Moderna's Stock Is Being Repriced, Not Re-Rated: Why Two Analysts Read the Same Rally in Opposite Directions
Published on 10/29/2026 at 03:10 | Editorial boerse-global.de
Two research notes landed on Moderna this week, and they point in opposite directions. William Blair cut its rating from "Outperform" to "Market Perform" on Tuesday, according to media reports, citing valuation after the stock's sharp rally rather than any disappointment in the melanoma study results. A day earlier, Piper Sandler had reaffirmed its "Overweight" call and lifted its price target to $230 from $167, pointing to the INTerpath-001 data.
The split captures the central question facing investors: good clinical news and a more cautious stock recommendation do not have to contradict each other. Equating the two mistakes medical progress for the separate matter of how much of that progress is already baked into the share price.
What the Trial Actually Showed
The scientific backdrop is the Phase 3 INTerpath-001 study. Per company statements, intismeran autogene combined with pembrolizumab reduced the risk of melanoma recurrence or death by 42% compared with pembrolizumab alone. The combination was tested in patients with surgically resected Stage IIB to IV melanoma.
Moderna presented the results at the ESMO conference and hosted a companion oncology investor day. Moderna and Merck published the data early following an information leak, a move the Associated Press reported on. According to Merck, the trial covered patients whose melanoma had been completely removed, and the detailed findings have been accepted for publication in the New England Journal of Medicine. A second figure from the study showed the risk of distant metastasis or death falling by 38%.
Should investors sell immediately? Or is it worth buying Moderna?
Those risk reductions anchor the investment case. On their own, though, they are not a valuation model. A trial success answers a medical question; a valuation has to weigh expectations about the future on top of it.
Two Houses, Two Yardsticks
The contrast between the two notes is instructive. William Blair's downgrade, reported yesterday, focused on the share price after the advance — not on any new clinical setback. Piper Sandler's higher target, by contrast, rested on the INTerpath-001 results themselves.
Moderna shares nevertheless climbed 2.6% on Tuesday to close at €190.22, with media coverage describing the move as a gain despite the downgrade as investors weighed the melanoma vaccine data against valuation concerns. In a separate session, the stock added 3.1%, again running counter to the more cautious rating. Neither move, however, offers an explanation for the advance.
Moderna at a turning point? This analysis reveals what investors need to know now.
The Next Catalyst
The next confirmed company event is the conference call on third-quarter 2026 results, which Moderna has scheduled for November 6 at 8:00 a.m. US Eastern time.
For now, the sensible approach is to keep the two levels apart: what the therapy has demonstrated, and what expectations justify the stock's price. At Moderna, the progress is concretely documented. The argument over its appropriate market value remains a separate question — and one Wall Street has yet to settle.
Ad
Moderna Stock: New Analysis - 29 October
Fresh Moderna information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
